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 Abstract. Retinoids are used in the clinical treatment of
oral squamous carcinoma, including both early and late
stages. Inter-individual variation in responsiveness, including
a common insensitivity of advanced stages, suggest that
changes in retinoid-related functions might characterize
tumor development. To investigate a genetic basis for this
hypothesis, an in vitro multi-step model of carcinogenesis
involving normal (NOK), SV40 T antigen-immortalized
(SVpgC2a) and malignant (SqCC/Y1) oral keratinocytes was
analysed under identical culture conditions using micro-array
technique (Affymetrix HG_U95A chip) for expression of
52 genes related to retinoid metabolism and actions. The
variable detection of between 22-26 transcripts in the cell
lines, involving binding/transport factors, receptors, trans-
criptional activators/repressors and responsive genes,
indicated specificity in regards to the expression of known
retinoid-related genes in oral keratinocytes. The transformed
cell lines variably exhibited differences as compared to NOK,
i.e., lower transcript levels for cellular retinol binding protein,
the cellular retinoic acid binding protein II (CRABP II) and
retinoic acid receptor Á, whereas in contrast, the levels of
CRABP I were higher. Transcripts for proteins interacting
with nuclear retinoid receptors were similarly expressed among
the cell types, whereas transcripts for retinoid-metabolizing
enzymes were generally not detected. Finally, transcripts of
retinoid-responsive genes, including RARRES3, RI58,
NN8-4AG and midkine, were variably expressed. The
overall results imply selective expression of retinoid-related
functions in normal and transformed keratinocytes, and that
cell transformation can impair the capacity for binding and
storage of retinol as well as retinoic acid-mediated signalling.
These multiple alterations are consistent with possible retinoid
insensitivity during oral carcinogenesis.
Introduction
Vitamin A and some of its analogues (retinoids) are established
modulators of epithelial cell differentiation in vivo and in vitro
(1,2). One of the major physiological functions of vitamin A
may be to prevent keratinization of non-keratinizing epithelia
(1,3). Squamous metaplasia, which develops during vitamin
A deficiency, can be reversed by supplementation with
retinoids (1). Furthermore, retinoids suppress squamous cell
differentiation that occurs spontaneously or is induced by
calcium ions in keratinocytes cultured from different human
tissues (1,3). Retinoids also suppress carcinogenesis in
experimental animals including a variety of tissues such as
the oral epithelium (4). Clinical studies have extended these
observations to human patient care and demonstrated the
efficacy of retinoids in suppressing oral premalignant lesions
and the occurrence of second primary carcinomas in patients
with head and neck cancer (5-7). These second primary
tumors, which occur at an incidence rate of 2-3% per year,
are the major cause of death after surgical resection of
early-stage head and neck cancer (8). Retinoid treatment is
however complicated by lack of activity in certain individuals
and from marginal activity in advanced cancer. These
observations clearly suggest that changes in the retinoid
sensitivity may underlie tumor development.
Increasing experimental evidence suggests that vitamin A
mediates its effects on the oral epithelial cells via its retinoic
acid (RA) derivatives (9-11). All-trans and 9-cis RA act as
ligands for the retinoid nuclear receptors (RARs, RXRs) (12).
These receptors are ligand-dependent transcription factors,
which bind to specific hormone response element (RARE,
RXRE) leading to transactivation of specific target genes
(13). Retinoic acids utilised by the cells are either taken up
from the blood circulation, or formed from vitamin A via
the subsequent action of various retinol and retinal dehydro-
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genases under the influence of intracellular retinol and
retinoic acid binding proteins (14). Apart from uptake and
synthesis, the amount of intracellular binding proteins and
the activity of degrading enzymes also influence the intra-
cellular levels and availability of retinoids for receptor inter-
action (14,15).
The application of serum-free conditions has permitted
the establishment of replicative cultures of normal oral
keratinocytes, and the growth of both immortalized and
malignant oral keratinocyte lines (16). Normal (NOK),
SV40 T antigen-immortalized (SVpgC2a) and malignant
(SqCC/Y1) human buccal keratinocytes model oral cancer
development on the basis that they reflect the eventual
acquisition of immortality, loss of p53 tumor suppressor
function and gain of a tumorigenic phenotype (16,17).
Furthermore, these normal and transformed keratinocyte cell
lines demonstrate keratin expression patterns similar to normal
tissue, oral dysplasia and well-differentiated oral squamous
cell carcinoma, respectively (18). The parallel examination of
such lines thus provides an in vitro model composed of the
various stages that lead to oral squamous carcinoma and
which can be used to study expression of genes involved in
retinoid action. On this basis, the current study analysed the
expression pattern of 52 retinoid-related genes in NOK,
SVpgC2a and SqCC/Y1 using the Affymetrix micro-array
chip technique. Notably, the use of one standardised culture
condition provided an identical environment and exogenous
influence on gene expression in the various cell types. The
results thus obtained, suggest the possibility of multiple
alterations in retinoid-related gene expression during oral
carcinogenesis, including mechanisms that might reduce












Preparation of labeled cRNA. Methods for cRNA preparation,
the hybridisation reactions and data analysis were provided
by the manufacturer (Affymetrix). Briefly, total RNA was
prepared with RNeasy (Qiagen) from 3x106 cells of each
type. Double-stranded cDNA was synthesized from 25 µg
total RNA using a cDNA synthesis kit (SuperScript Choice
system; Gibco BRL Life Technologies). Labeled cRNA
was in vitro transcribed with 1.5 µg cDNA as template
incorporating biotinylated CTP and UTP (Enzo RNA Trans-
cript Labeling Kit; Enzo Diagnostics). The cRNA was purified
with RNeasy affinity columns (Qiagen) and subsequently
fragmented in 40 mM Tris-acetate, pH 8.1, 100 mM potassium
acetate, 30 mM magnesium acetate at 94˚C for 35 min.
Array hybridization. cRNA (10 µg) and samples for internal
controls were hybridized to oligonucleotide arrays HG_U95A,
(Affymetrix) at 45˚C for 16 h according to the manufacturer's
protocol. Arrays were washed under stringent conditions,
stained with streptavidine-phycoerythrine (Molecular Probes),
washed again and subsequently scanned at 570 nm using a
Hewlett Packard Gene Array scanner. Obtained data were
analyzed with GeneChip 3.1 software (Affymetrix).
Visualisation of microarray data was performed by Cluster
and TreeView software (downloaded from http://www.rana.
lbl.gov). All chips were scaled to a target intensity of 250 for
inter-array comparisons. The scale-factors for chip NOK (1),
NOK (2), SVpgC2a (1), SVpgC2a (2), SqCC/Y1 (1) and
SqCC/Y1 (2) were 3.19, 5.06, 1.76, 3.39, 2.95 and 3.83
respectively. The presence of individual genes was described
by the absolute call (based on Pos/Neg Ratio, Positive Fraction
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Figure 1. Expression pattern of genes involved in retinoid binding and
metabolism as detected by Affymetrix gene array in NOK, SVpgC2a and
SqCCY/1. The colour code used to express the average difference is shown
below the gene panels. A, absent; P, present; M, marginally present.
and Log Average Ratio), while the changes in the expression
levels were quantified by the average difference (for further
details see GeneChip 3.1 Expression Analysis Algorithm
Tutorial). Gene expression was considered induced/repressed
based on a two-fold change among samples. This limit is in
agreement with other mammalian studies (19).
Results
Micro-array chips with oligonucleotides corresponding to
12558 human genes were hybridised with labelled cRNA
prepared from NOK, immortalised (SVpgC2a) and malignant
(SqCC/Y1) human oral keratinocytes to determine the
expression level of retinoid-related genes. The results were
from two separate experiments/hybridisations using different
NOK lines and passages of SVpgC2a and SqCC/Y1. The
total number of transcripts found in NOK, SVpgC2a and
SqCC/Y1 in experiments 1 and 2 were 3830/3958, 4865/4467
and 3887/4533, respectively. Altogether 52 genes involving
different retinoid-related functions, i.e., binding/transport,
metabolism, receptors, transcriptional activators/repressors,
and finally, responsive genes, were examined. Probes for
enzymes related to the retinol storage, e.g., lecithin-retinol-
acyltransferase (LRAT) or acyl-CoA-retinol acyltransferase,
were absent on the chip. In contrast, probes for cellular
retinoic acid binding proteins I and II, alcohol dehydrogenase 1
or RARÁ were represented by two different probe sets. In total
22, 26 and 23 transcripts of the 52 genes were detected by the
HG_U95A array in NOK, SVpgC2a and SqCC/Y1,
respectively. The results are shown in Figs. 1-3 and discussed
in detail below.
The transcripts of the retinol and RA binding proteins
(CRBP-I, CRABP-II) responsible for storage and processing
of retinol and RA (20) were all detected in the NOK lines,
while no evidence was found for CRABP-I expression.
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Figure 2. Expression pattern of genes involved in retinoid signalling as
detected by Affymetrix gene array in NOK, SVpgC2a and SqCCY/1. The
colour code used to express the average difference is shown below the gene
panels. A, absent; P, present, M, marginally present.
Figure 3. Expression pattern of four retinoid-responsive genes as detected by
Affymetrix gene array. in NOK, SVpgC2a and SqCCY/1. The expression
level of two ‘house-keeping’ genes, ß-actin and glycerinaldehyde-3-
phosphate dehydrogenase, used as positive controls, is also shown. The
colour code used to express the average difference is shown below the gene
panels. A, absent; P, present, M, marginally present.
Transcripts for CRBP-I and CRABP-II were absent, while
that of CRABP-I was present, in at least one of the four
hybridisations in SVpgC2a and SqCC/Y1. All cell types were
negative for retinol binding protein (RBP4), the transthyretin
gene (TTR) and the interstitial retinoid binding protein
(RBP3) involved in extracellular transport of retinoids (20).
Thus, these three genes served as internal negative controls
in the experiments.
Members of four enzyme families may participate in
the conversion of retinol to retinoic acid (21). No transcripts
were found for enzymes belonging to the short-chain
dehydrogenase family responsible for the conversion of
retinol to retinal, the first step in the synthesis of RA, such as
retinol dehydrogenase (RODH), the microsomal NAD+-
dependent retinol dehydrogenase (RODH-4), short-chain
dehydrogenase (SDR1), and 9-cis-/11-cis-retinol dehydro-
genase (RDH5). Members of the alcohol dehydrogenase
(ADH1A B C, ADH4) family, suggested also to participate
in the retinol metabolism, were absent with the exception of
ADH1B, which was detected in one of the NOK lines. There
was no probe for the ADH2 enzyme on the chip.
Four enzymes have been suggested to participate in the
conversion of retinal to RA, i.e., two alcohol dehydrogenases
[retinal dehydrogenase (RALDH1=ALDH1) and RALDH2]
and two cytochrome P450 types (P450 1A1 and 1A2). Message
for RALDH1 was not detected. RALDH2 was detected in
one of the two hybridisations in NOK and SVpgC2a, but not
in SqCC/Y1. CYP1A1 was not detected in any of the cell
lines, and no probe was present for the CYP1A2 message on
the chip.
The retinoic acid 4-hydroxylase (CYP26A1) responsible
for the degradation of RA (22) was detected in only one of
the analysis of SVpgC2a.
Analysis of members of the nuclear retinoid receptor
family (12) indicated presence of RAR· in NOK and
SqCC/Y1, while no expression was detected in SVpgC2a.
RARß was not detected in any of the cell lines. RARÁ was
detected in three of the four repeats in NOK, in one of the
four repeats in the SVpgC2a, while its message was not
detected in SqCC/Y1. NOK and SVpgC2a showed transcripts
of RXRß, whereas SqCC/Y1 showed presence of RXR ·, ß
and Á in at least one of the probe sets.
Members of the nuclear retinoid receptor family mediate
their effects on the basal transcriptional machinery via
interacting with other nuclear proteins (23). In the presence
of the specific ligand they activate transcription via binding
to various members of co-activators. Some of the major
co-activators can be classified to the p160 family, including
SRC-1/N-CoA1, GRIP-1/TIF2/N-CoA2 and ACTR/
pCIP/RAC3/AIB-1/N-CoA3; or to the co-integrators such
as CBP (CREBBP), p300 and pCAF. Of the p160 family,
N-CoA1 was present in one of the analyses of SqCC/Y1.
N-CoA2 was not detected in the cell types. N-CoA3 was
marginally expressed or not detected in NOK, but it was
present in SVpgC2a and in SqCC/Y1. Of the co-integrators,
CREBBP was not detected in NOK, but it was present in
SVpgC2a and in one of the repeats in SqCC/Y1. p300 was
detected in one of the repeats in NOK and SqCC/Y1 cell lines.
pCAF was not detected in any of the cell lines. Of additional
co-activator proteins, expression of TIF-1· (transcriptional
intermediary factor) was detected in one of the repeats in
SVpgC2a, while PSMC5 was expressed by all cells. Co-
activator family members often exhibit histone acetyl-
transferase activity and other histone acetyltransferases may
also be transciptionally active (24). Histone acetyltransferases
HAT1, Gcn5L2, MOZ and HBOA were expressed by each
cell lines with no significant change in the expression level,
except for Gcn5L2, which was elevated in SqCCY/1. In
contrast, message for MORF or Tip60 histone acetyl-
transferases was not detected in any of the cell lines.
In the absence of specific ligand, RARs repress basal
transcription by binding to promoters of target genes and by
interaction with two co-repressors N-Cor (nuclear receptor
co-repressor) and SMRT (silencing mediator of retinoid
and thyroid hormone receptor) (25,26). Analogous to the
co-activator complexes, these co-repressors recruit histone
deacetylases (HDACs) (27). While SMRT was shown to
recruit class I HDACs, such as HDAC1, HDAC2, HDAC3
and HDAC8, N-Cor reacts with class II HDACs, such as
HDAC4, HDAC5 and HDAC7 (28). N-Cor1 and SMRT
were expressed in each cell line, while no message for N-Cor2
was detected. HDAC 1, 2, 3 and 5 were expressed in each
cell line, HDAC2 showing a higher expression in SVpgC2a
relative to NOK. HDAC4 was detected in one of the repeats
in SVpgC2a, HDAC6 was detected in one repeats in
ScCC/Y1, while HDAC7 was not expressed. There was no
probe for HDAC8 on the chip.
Finally, expression of some retinoid-responsive genes
was analysed. RARRES3 (or TIG3), the retinoic acid receptor
responder 3 (29), was marginally expressed in one of the
SVpgC2a preparations. mRNA of the NN8-4AG (30) was
detected in one of the two SVpgC2a repetitions. The retinoic
acid and interferon inducible protein, RI58 (31) was detected
in one of the analyses of NOK and in both analyses of
SVpgC2a. Finally, the retinoic acid inducible factor midkine
(32) was not detected in NOK but it was detected at high
levels in one analysis of each of the transformed lines.
Discussion
In this study, the expression pattern of 52 retinoid-related
genes was studied under identical serum-free conditions
using an in vitro model of oral carcinogenesis that includes
normal, immortalized and malignant cells. The existence of
transcripts from genes coding for retinoid-related functions
were analyzed based on the concept that the responsiveness
of oral keratinocytes may decrease during malignant trans-
formation (33). As discussed separately for various retinoid-
related genes, including binding/transport, metabolism,
receptors, transcriptional activators/repressors and responsive
genes, the overall results supported an association between
impaired retinoid sensitivity and oral carcinogenesis.
To maintain solubility, retinoids must be bound to
proteins in an aqueous environment. Hepatic proteins have
been reported to participate in the extra-cellular transport of
retinoids (20). As expected for extra-hepatic tissues, the oral
keratinocyte lines were negative for retinol binding protein
and transthyretin, and furthermore, the cells were negative
for the interstitial retinoid binding protein that is typically
expressed in the eye (20).
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The uptake and the storage of retinoids within the cells
are mediated by various cellular retinoid binding proteins
including CRBP-I, CRABP-I and II. CRBP-I facilitates
retinol uptake, delivers retinol to LRAT for esterification and
storage, and interacts with several enzymes that metabolise
retinol or retinal, providing the retinol and retinal substrate
for their action (20). Of the cellular retinoid-binding proteins,
CRBP-I manifests the widest distribution, expressed in most
retinoid-sensitive tissues. Accordingly, CRBP-I was clearly
detected in NOK, however, it was not detected in SqCC/Y1.
CRBP-1-deficient mice have decreased capacity to store
incoming retinol and to maintain retinyl ester stores, and
show enhanced sensitivity to vitamin A deficiency (34)
suggesting that loss of the CRBP-1 function might have
the same impact on carcinoma cells. In agreement, loss of
CRBP-1 is an early event during transformation of breast
epithelium, a known retinoid-sensitive tissue (35).
Though the two cellular RA binding proteins possess
similar RA-binding affinities, they display distinct pattern of
expression across cells and developmental stages, and serve
specific and distinct roles in RA biology (36,37). Elevated
CRABP-I expression in F9 teratocarcinoma cells enhanced
formation of polar metabolites from RA and blocked RA-
induced differentiation (38). Accordingly, increased CRABP-I
expression, as noted in SqCC/Y1 relative to the other cell
types, may lead to decreased availability of RA. In contrast,
CRABP-II sensitises cells to RA and facilitates transfer of
RA to RAR via direct interaction with the nuclear receptor
(15,39). CRABP-II was present in NOK but undetected in
SqCC/Y1, whereas CRABP-I was undetected in NOK but
present in SqCC/Y1. High and low levels of CRABP-II were
previously reported for normal keratinocytes and SqCC/Y1,
respectively, using semi-quantitative RT-PCR (9). Overall,
the expression pattern for CRABP proteins implied
decreased RA sensitivity in SqCC/Y1 as compared to NOK.
The pathway for conversion of retinol to RA involves
oxidation of retinol to retinal followed by oxidation of retinal
to retinoic acid, either in free or in CRBP-bound form.
Enzymes involved in retinol and retinal metabolism belong to
four distinct families; i.e. alcohol dehydrogense, short-chain
dehydrogenase/reductase, aldehyde reductase and cyto-
chrome P450 (21). The microarray results implied low or
absent, i.e., undetected, expression of these enzymes in the
cell lines, with the exception of RALDH2 (41), that was
detected in one of the two probe sets in NOK and SVpgC2a.
The CYP26A1 (retinoic acid 4-hydroxylase), an enzyme
responsible for the catabolism of retinoic acid (22), was
detected in only one of the assessments of SVpgC2a. Elevated
enzyme levels of this enzyme were previously reported in head
and neck cancers potentially leading to increased retinoid
metabolism and decreased retinoid availability (42).
The spatio-temporal distribution of various nuclear
retinoic acid receptors during embryonic development and
tissue-specific expression patterns suggest differential roles
of these receptors in retinoid-regulated signalling pathways
(43). RAR· and RARÁ but not RARß, was detected in NOK
in agreement with previous studies in keratinocytes cultured
from different regions of normal oral mucosa (44). Message
for RARß was not detected in SVpgC2a or SqCC/Y1, whereas
message for RAR· was detected in SqCC/Y1 but not in
SVpgC2a. In agreement, presence of RAR· and lack of
RARß expression was previously reported for SqCC/Y1 (9).
Only one of the four repeats for RARÁ was positive in
SVpgC2a and none of the repeats were positive in SqCC/Y1.
The transcript levels for RARÁ in SqCCY1 are likely below
the detection limit of the micro-array, since SqCC/Y1 was
previously shown to express low levels of RARÁ and to
respond to RARÁ specific compounds (9). SqCC/Y1
transfected with RARÁ show increased sensitivity to growth
inhibition by RA while antisense-transfection causes the
opposite effect (10). Furthermore, the expression level of
RARÁ correlates to RA sensitivity of head and neck squamous
carcinoma cell lines (45). In this regard, the low RARÁ
expression levels of SVpgC2a and SqCC/Y1 as detected
by micro-array indicate that both lines may be relatively
insensitive to retinoid actions.
RXRs serve as dimerisation partners for the RAR receptors.
Unlike the RAR receptors that are stimulated by both all-
trans and 9-cis RA, the RXRs are selectively stimulated by
9-cis RA (12). The micro-array results suggested increased
expression of RXRs in the malignant state since RXR· and
RXRÁ was selectively expressed in SqCC/Y1, whereas
RXRß was detected in one repetition of all cell types. In
agreement, increased level of RXRs was previously reported
for oral carcinomas (46). The role of RXRs for retinoid
signalling in oral keratinocytes remains unclear. However,
stimulation of RXR might inhibit the growth inhibitory
signals mediated by the RAR receptors, since NOK are
growth inhibited by nano-molar levels of all-trans RA and
µmolar levels of 9-cis RA (unpublished observation). In this
regard, increased RXR expression in the malignant state
might again lead to decreased retinoid sensitivity.
Various nuclear proteins interact with the retinoid receptors
thereby mediating repression or activation of specific target
genes. In absence or presence of receptor ligand, complexes
of corepressors or coactivators mediate histone deacetylation
or acetylation, respectively, and such reversible acetylation
is thought to regulate protein to DNA interactions and
transcription (27,47). The co-activator complex members,
ACTR/pCIP/RAC3/AIB-1/N-CoA3 (48), its binding partner
CBP/p300 (49), PSMC5 (50), and that of the histone
acetyltransferases HAT1, Gcn5L2 belonging to the GNAT
superfamily, and MOZ and HBOA belonging the MYST
family (24) were detected at similar expression levels in all
cell types with the exception of Gcn5L2, the message of
which was elevated in SqCC/Y1. The co-repressor complex
members, SMRT, Ncor-1, and the histone deacetylase 1,2,3
and 5 were detected at similar expression level in all cell
types except for higher levels of HDAC2 in SVpgC2a. The
expression levels of HDAC4 and 6 may be close to the
detection limit of the micro-array assay since their transcripts
were detected in only one probe set. Though some reports
suggest that proteins such as CBP/p300 or MOZ may act to
suppress cancer development (51,52), the current results in
the oral keratinocyte lines did not imply that transformation
induces significant alteration in the expression of the nuclear
co-activators and co-repressors.
Finally, expression of certain retinoid-regulated genes
was implicated for oral epithelium from positive detection in
at least one of the analysis of the respective cell types (Fig. 3).
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The cellular function of NN8-4AG (30) is unknown, whereas
RARRES or TIG3 (29) is considered a tumor-suppressor that
is down-regulated in B-cell lymphoid leukemia progression
(53). The retinoic acid and interferon inducible protein
(RI58) has a known involvement in myeloid differentiation
(31). Midkine is a heparin-binding growth/differentiation
regulating factor that promotes neuronal growth (54,55). Its
expression in human epidermal keratinocytes was also
associated to promoted growth (56). On the basis of elevated
serum levels in cancer patients (57), the possibility of
selective expression in the immortal and malignant states
indicates an association also to the development of oral
squamous carcinomas. As for the other retinoid-related
functions investigated in this study, future assessments of
tissue-specificity or variability among cell lines should
consider methods of even higher sensitivity than microarray,
e.g., quantitative RT-PCR (58), in order to more accurately
determine presence or absence of gene expression in
quantitative terms.
In conclusion, application of the micro-array chip techno-
logy allowed a simultaneous expression analysis of a large
number of retinoid-related genes in a three-step progression
model of oral carcinogenesis. The expression patterns
under identical growth conditions indicated alterations in
regards to the metabolism and signalling of retinoids,
ultimately implicating decreased retinoid sensitivity during
cell transformation. The noted retinoid-related changes
included those that could affect binding, storage, synthesis
and signalling, and finally, genes that are regulated by
retinoids. The overall analyses thus suggest a variety of
mechanisms for normal and disturbed retinoid actions in oral
epithelium, some of which are likely to be testable in future
assessments of growth and cell death regulation in cultured
normal and transformed oral keratinocytes.
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